BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Reference Citation Analysis]
2 Chen Y, Yao Y, Zhao K, Liu C, Yuan Y, Sun H, Huang D, Zheng Y, Zhou Y, Chen J, Wang Y, Wu C, Zhang B, Guan Y, Li F, Pei R, Chen X, James Ou J. DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation. J Virol. [DOI: 10.1128/jvi.00585-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhong YW, Shi YM, Chu F, Liu J, Shi C, Xu JJ, Liu P, Bai YJ, Xiao XH, Zhang XC, Zhang M. Prediction for HBsAg seroconversion in children with chronic hepatitis B. BMC Infect Dis 2021;21:1211. [PMID: 34863101 DOI: 10.1186/s12879-021-06883-1] [Reference Citation Analysis]
4 Wang X, Chi X, Wu R, Xu H, Gao X, Yu L, Liu L, Zhang M, Tan Y, Niu J, Jin Q. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4. [PMID: 33407619 DOI: 10.1186/s12985-020-01471-2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wang X, Wang Z, Chi X, Wu R, Jin Q, Xu H, Gao X, Yu L, Chen Y, Shang J, Liu L, Zhang S, Jiang Y, Zhang M, Tong Q, Zhang L, Tan Y, Ma A, Dang S, Xu B, Jin Z, Li J, Li X, Lu F, Niu J. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int J Infect Dis 2020;99:171-8. [PMID: 32721532 DOI: 10.1016/j.ijid.2020.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Yll M, Cortese MF, Guerrero-Murillo M, Orriols G, Gregori J, Casillas R, González C, Sopena S, Godoy C, Vila M, Tabernero D, Quer J, Rando A, Lopez-Martinez R, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F. Conservation and variability of hepatitis B core at different chronic hepatitis stages. World J Gastroenterol 2020; 26(20): 2584-2598 [PMID: 32523313 DOI: 10.3748/wjg.v26.i20.2584] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kumar N, Sharma S, Kumar R, Tripathi BN, Barua S, Ly H, Rouse BT. Host-Directed Antiviral Therapy. Clin Microbiol Rev 2020;33:e00168-19. [PMID: 32404434 DOI: 10.1128/CMR.00168-19] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
9 Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: Significance and Management. J Clin Med. 2020;9. [PMID: 31940817 DOI: 10.3390/jcm9010202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep 2018;15:172-81. [PMID: 29572624 DOI: 10.1007/s11904-018-0379-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Wang Z, Kawaguchi K, Honda M, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. Distinct notch signaling expression patterns between nucleoside and nucleotide analogues treatment for hepatitis B virus infection. Biochem Biophys Res Commun 2018;501:682-7. [PMID: 29752943 DOI: 10.1016/j.bbrc.2018.04.236] [Reference Citation Analysis]
12 Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res 2019;49:51-63. [PMID: 30350374 DOI: 10.1111/hepr.13277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
13 Alidjinou EK, Michel C, Canva V, Ajana F, Hober D, Bocket L. Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues. J Med Virol 2018;90:989-93. [PMID: 29315722 DOI: 10.1002/jmv.25028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Murai K, Shirasaki T, Honda M, Shimizu R, Shimakami T, Nakasho S, Shirasaki N, Okada H, Sakai Y, Yamashita T, Kaneko S. Peretinoin, an Acyclic Retinoid, Inhibits Hepatitis B Virus Replication by Suppressing Sphingosine Metabolic Pathway In Vitro. Int J Mol Sci 2018;19:E108. [PMID: 29360739 DOI: 10.3390/ijms19020108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Chirumbolo S. Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway. Inflamm Res 2018;67:203-5. [DOI: 10.1007/s00011-017-1111-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Dandri M, Petersen J. Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. Clin Infect Dis 2016;62 Suppl 4:S281-8. [PMID: 27190317 DOI: 10.1093/cid/ciw023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
17 Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9:156. [PMID: 28635668 DOI: 10.3390/v9060156] [Cited by in Crossref: 63] [Cited by in F6Publishing: 81] [Article Influence: 12.6] [Reference Citation Analysis]
18 Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281. [PMID: 27639844 DOI: 10.1016/j.jhep.2016.08.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 95] [Article Influence: 14.5] [Reference Citation Analysis]
19 Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res. 2015;122:91-100. [PMID: 26272257 DOI: 10.1016/j.antiviral.2015.08.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 11.9] [Reference Citation Analysis]